reports
Enlivex Announces Authorization from the Danish Regulatory Agency for ...
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis Nes-Ziona, Israel, April 16, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Danish Medicines Agency (DKMA) authorized the expansion into Denmark of the Company’s multi-country, randomized, controlled Phase I/II trial evaluating AllocetraTM in up to 160 patients with moderate to severe kn...
Supercomnet Technologies Berhad: 1 director
A director at Supercomnet Technologies Berhad sold 3,000,000 shares at 1.277MYR and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last...
Ancom Nylex Berhad: 1 director
A director at Ancom Nylex Berhad bought 2,000,000 shares at 1.000MYR and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
Director/PDMR Shareholding
Director/PDMR Shareholding 16 April 2024 OSB GROUP PLC (the Company) Notification of Transactions of Persons Discharging Managerial Responsibilities (PDMRs) The Company notifies changes in the PDMRs interests in the ordinary shares of £0.01 each (Shares) of the Company, arising from Awards that vested under the 2021 Deferred Share Bonus Plan (DSBP) and 2021 Performance Share Plan (PSP). The 2021 DSBP and PSP were granted on 15 April 2021 at a price of £4.920 per Share being the closing price prior to the date of grant. NameNumber of DSBP Shares VestingNumber of PSP Shares VestingNumber...
StoneCo Ltd. to Announce First Quarter 2024 Financial Results on May 1...
StoneCo Ltd. to Announce First Quarter 2024 Financial Results on May 13, 2024 and Adopt New Internal Accounting Policy GEORGE TOWN, Grand Cayman, April 16, 2024 (GLOBE NEWSWIRE) -- StoneCo Ltd. (Nasdaq: STNE, B3: STOC31) (“Stone”) announces that it will release its first quarter 2024 financial results on Monday, May 13, 2024 after the market closes and will host a conference call that afternoon at 5:00pm ET (6:00pm BRT) to discuss the results. The Company also announces that, beginning in the first quarter of 2024, it will adopt a new internal accounting policy for the recognition of mem...
Nilörngruppen: Presentation Interim Report Q1, 2024
Nilörngruppen: Presentation Interim Report Q1, 2024 Presentation Nilörn Interim Report Q1, 2024 A presentation will be held via Teams 17/4 at 08.30 am CET, where the CEO presents the report. You can participate by register on the link below: For further information about Nilörn, please contact: Krister Magnusson, CEO Tel: . E-mail: General about Nilörn Group Nilörn Group is a global company, founded in the 1970s, with expertise in how to add value to brands through branding and design in the form of labels, packaging and accessories, primarily to customers in the fashion and clothing...
Nilörngruppen: Presentaiton Delårsrapport Q1, 2024
Nilörngruppen: Presentaiton Delårsrapport Q1, 2024 Presentation Delårsrapport Q1, 2024 En presentation kommer hållas via Teams 17/4 kl. 08.30, där VD presenterar rapporten. Du kan delta genom att registrera dig på nedanstående länk: För ytterligare information om Nilörn, kontakta: Krister Magnusson, CEO Tel: . E-post: Generellt om NilörngruppenNilörngruppen är ett globalt företag, grundat på 1970-talet, med expertis inom hur man adderar värde för varumärken genom varumärkesbyggande och design i form av etiketter, förpackningar och accessoarer, främst till kunder inom m...
BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 C...
BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment — Amendment replaces saline injections with sham injections in the control group — MELVILLE, N.Y., April 16, 2024 (GLOBE NEWSWIRE) -- . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:), a clinical stage company focused on stem cell-based therapies, today announced that the U.S. Food and Drug Administration (“FDA”) has cleared an important amendment to the protocol of the ongoing Phase 2 study investigating the use of BRTX-100, the Company’s lead cell therapy candidate, in treat...
Alliance Trust PLC - Net Asset Value
Alliance Trust PLC - Net Asset Value ALLIANCE TRUST PLC At the close of business Monday 15 April 2024: The Company’s NAV per ordinary share, valued on a bid price basis with Debt at Par, was - excluding income, 1258.1p - including income, 1262.4p The Company’s NAV per ordinary share, valued on a bid price basis with Debt at Fair Value, was - excluding income, 1262.5p - including income, 1266.8p For further information, please contact: - Juniper Partners LimitedTel. +44 (0)131 378 0500 Notes Net Asset Values are calculated in a...
CIC39 Corporation: 1 director
A director at CIC39 Corporation maiden bought 101,600 shares at 0.000VND and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...
Tims China Announces Earnings Release Date For Q4 and Full Year 2023 R...
Tims China Announces Earnings Release Date For Q4 and Full Year 2023 Results & Conference Call SHANGHAI, China and NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- TH International Limited (“Tims China” (Nasdaq: THCH)), the exclusive operator of Tim Hortons coffee shops and Popeyes restaurants in China, will release its fourth quarter and full year results before market opening on Thursday, April 18, 2024. The company will hold a conference call on Thursday, April 18, 2024, at 8:00 am Eastern Time (or Thursday, April 18, 2024, at 8:00 pm Beijing Time) to discuss its financial results. The ca...
ParaZero Develops Counter Drone Solutions Leveraging Its Unique Techno...
ParaZero Develops Counter Drone Solutions Leveraging Its Unique Technology The counter unmanned aircraft system (C-UAS) market is estimated to reach over $15 billion by 2032 Tel Aviv, Israel, April 16, 2024 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (Nasdaq: PRZO) (the "Company” or “ParaZero”), an aerospace company focused on drone technologies for commercial drones, defense drones and urban air mobility aircraft, recently announced its intention to enter the counter unmanned aircraft system (C-UAS or anti-drone) market, by developing dedicated solutions based on its advanced techn...
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an A...
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to LX2006, the company’s AAVrh.10hFXN-based gene therapy candidate for the treatment of F...
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annu...
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID) Phio’s lead clinical product candidate, PH-762, is the subject of three new dermatological posters MARLBOROUGH, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting new data about its lead clinical candidate, PH-762, an INTASY...
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 202...
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024 CANTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that first quarter of fiscal year 2024 financial results will be reported after the market closes on Thursday, May 9th. Management will host a conference call at 5:00 p.m. Eastern Time ...
Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates ELX-02 Granted Orphan Drug Designation (ODD) from U.S. Food and Drug Administration (FDA) for Treatment of Alport Syndrome Pre-Investigational New Drug (IND) Meeting Requested with U.S. FDA for ELX-02 to Discuss Planned next Study In Nonsense Mutation Alport Syndrome Signed Global Licensing Partnership for ZKN-013 with Almirall Pharmaceuticals with $3M upfront and up to $470M in milestones and Tiered Royalties on Global Sales New Paper Published on Autosomal Dominant Polycystic Kidney Disease (ADPKD) shows that ELX-...
Standard Uranium Reports on Recent Exploration Insights at the Sun Dog...
Standard Uranium Reports on Recent Exploration Insights at the Sun Dog Project with Option Partner Aero Energy Ltd. Sun Dog is host to globally significant former uranium producer. VANCOUVER, British Columbia, April 16, 2024 (GLOBE NEWSWIRE) -- Standard Uranium Ltd. (“Standard Uranium” or the “Company”) (TSX-V: STND) (OTCQB: STTDF) (Frankfurt: FWB:9SU) is pleased to provide a comprehensive summary of exploration insights and historical data gathered at its Sun Dog Uranium Project (“Sun Dog”, or the “Project”), currently under a three-year earn-in option agreement with Aero Energy Ltd. (...
Osisko Metals Reports Preliminary Metallurgical Testwork Results From ...
Osisko Metals Reports Preliminary Metallurgical Testwork Results From Gaspé Copper MONTREAL, April 16, 2024 (GLOBE NEWSWIRE) -- Osisko Metals Incorporated (the "Company" or "Osisko Metals") (; ; ) is pleased to announce preliminary metallurgical and grindability testwork results from the Gaspé Copper Project located near Murdochville in the Gaspé peninsula in Québec. Testwork was performed on eighteen composite samples of mineralized drill core from selected intersections of the 2023 drill program at Copper Mountain, and employed a conventional copper-molybdenum flotation flowsheet and r...
Métaux Osisko dévoile les résultats préliminaires des essais métallurg...
Métaux Osisko dévoile les résultats préliminaires des essais métallurgiques sur le gîte de cuivre de Mines Gaspé MONTRÉAL, 16 avr. 2024 (GLOBE NEWSWIRE) -- Métaux Osisko Incorporée (la « Société » ou « Métaux Osisko ») (; ; ) a le plaisir d'annoncer les résultats préliminaires des essais métallurgiques et de broyabilité du projet de cuivre de Mines Gaspé, situé près de Murdochville, dans la péninsule gaspésienne, au Québec. Les essais ont été effectués sur dix-huit échantillons composites de carottes de forage minéralisées provenant d'intersections sélectionnées dans le cadre du programm...
Enovix Announces Fab2 Manufacturing Milestones
Enovix Announces Fab2 Manufacturing Milestones FREMONT, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- (“Enovix”) (Nasdaq: ENVX), a global high-performance battery company, today announced it has completed Factory Acceptance Testing (“FAT”) for its Gen2 Agility Line and is on track to produce first silicon battery samples from Fab2 in the second quarter of 2024. “I’m proud to announce the team has completed our rigorous FAT process for all machines that make up our Agility Line,” said Ajay Marathe, Chief Operating Officer at Enovix. “SAT is also well underway. Both FAT and SAT processes ens...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.